To further examine the preventive effect of an intracerebroventricular injection of G2-β-CD, we evaluated the histological changes in whole Npc1−/− mouse brain by osteoactivin/glycoprotein non-metastatic protein B (GPNMB)-immunostaining, a potential marker of NPC manifestation and lysosomal dysfunction [24,25]. The gene discussed is GPNMB; the disease is nasopharyngeal carcinoma.